Skip to main content

Table 3 Analysis of risk factors for pN2–3a

From: Development of nomograms to predict axillary lymph node status in breast cancer patients

  Univariate analysis Multivariate analysis
  N0 N1–3 P b OR(95%) P
  n %a n %+
Age Group
 Age < =50Yrs 3229 66.30 1641 33.70 <0.001 1  
 50-60Yrs 2958 66.20 1510 33.80 1.06(0.97–1.16) 0.202
  > 60Yrs 3917 62.49 2351 37.51 1.23(1.14–1.34) <0.001
Location Of Lesions
 UIQ 1374 69.39 606 30.61 <0.001 1  
 UOQ 5753 64.16 3213 35.84 1.30(1.17–1.45) <0.001
 LOQ 1300 63.82 737 36.18 1.38(1.20–1.59) <0.001
 LIQ 788 69.31 349 30.69 1.15(0.98–1.36) 0.095
 Central 889 59.83 597 40.17 1.36(1.17–1.58) <0.001
T-Stage
 T1 4589 76.36 1421 23.64 <0.001 1  
 T2 4993 60.53 3256 39.47 1.83(1.69–1.97) <0.001
 T3 522 38.75 825 61.25 3.97(3.48–4.52) <0.001
Histology
 IDC 8027 66.32 4076 33.68 <0.001 1  
 ILC 761 52.02 702 47.98 1.96(1.73–2.22) <0.001
 IDC & ILC 570 61.16 362 38.84 1.27(1.10–1.47) 0.001
 IDC & Others 272 67.83 129 32.17 0.91(0.73–1.13) 0.396
 IMC 59 81.94 13 18.06 0.44(0.24–0.82) 0.01
 Others 415 65.35 220 34.65 1.02(0.85–1.21) 0.848
Grade
 I 1482 75.88 471 24.12 <0.001 1  
 II 4433 65.51 2334 34.49 1.30(1.15–1.47) <0.001
 III 4140 60.98 2649 39.02 1.44(1.26–1.64) <0.001
 Others/NA 49 50.52 48 49.48 1.48(0.95–2.30) 0.08
Estrogen Receptor
 Negative 1892 62.18 1151 37.82 <0.001 1  
 Positive 8212 65.37 4351 34.63 1.05(0.92–1.19) 0.467
Progesterone Receptor
 Negative 2809 61.93 1727 38.07 <0.001 1  
 Positive 7295 65.90 3775 34.10 0.93(0.84–1.04) 0.219
Her2
 Negative 8541 65.96 4408 34.04 <0.001 1  
 Positive 1563 58.83 1094 41.17 1.30(1.18–1.42) <0.001
Lymphovascular Invasion
 Not Present 5632 74.12 1966 25.88 <0.001 1  
 Present 4472 55.84 3536 44.16 2.11(1.96–2.26) <0.001
  1. ALN axillary lymph node, Yrs years old, HER2 human epidermal growth factor receptor 2, LIQ lower-inner quadrant, LOQ lower-outer quadrant, UIQ Upper-inner quadrant, UOQ Upper-outer quadrant, N/A not available, IDC infiltrating ductal carcinoma, ILC infiltrating lobular carcinoma, IMC invasive mucinous carcinoma, NS non-significant
  2. aOnly patients with positive nodes were included. Patients with <10 axillary lymph nodes examined <10 but >1 positive ALNs were excluded
  3. bRow percentage was shown.
  4. ***Chi-square test was used for univariate analysis